Deutsche Bank Ag\ Immuno Gen, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $10.5 Million - $25.2 Million	840,814 Added 373.59%	1,065,880 $31.6 Million
Q3 2023 Nov 09, 2023	SELL	$14.09 - $19.87 $43.4 Million - $61.2 Million	-3,079,661 Reduced 93.19%	225,066 $3.57 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $850,811 - $4.55 Million	226,883 Added 7.37%	3,304,727 $62.4 Million
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $147,842 - $198,197	40,284 Added 1.33%	3,077,844 $11.8 Million
Q4 2022 Feb 13, 2023	BUY	$4.55 - $6.31 $141,391 - $196,083	31,075 Added 1.03%	3,037,560 $15.1 Million
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $109,800 - $158,573	-24,509 Reduced 0.81%	3,006,485 $14.4 Million
Q2 2022 Aug 11, 2022	BUY	$3.15 - $5.76 $268,622 - $491,195	85,277 Added 2.89%	3,030,994 $13.6 Million
Q1 2022 May 13, 2022	BUY	$4.26 - $7.48 $4.7 Million - $8.26 Million	1,104,077 Added 59.95%	2,945,717 $14 Million
Q4 2021 Feb 11, 2022	BUY	$4.75 - $7.5 $29,421 - $46,455	6,194 Added 0.34%	1,841,640 $13.7 Million
Q3 2021 Nov 04, 2021	SELL	$5.02 - $6.59 $63,989 - $84,002	-12,747 Reduced 0.69%	1,835,446 $10.4 Million
Q2 2021 Aug 11, 2021	SELL	$5.79 - $8.6 $6.64 Million - $9.86 Million	-1,145,979 Reduced 38.27%	1,848,193 $12.2 Million
Q1 2021 May 13, 2021	BUY	$6.5 - $10.53 $921,219 - $1.49 Million	141,726 Added 4.97%	2,994,172 $24.3 Million
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $3.97 Million - $8.22 Million	1,073,055 Added 60.3%	2,852,446 $18.4 Million
Q3 2020 Nov 12, 2020	BUY	$3.45 - $4.89 $3.32 Million - $4.7 Million	962,081 Added 117.71%	1,779,391 $6.41 Million
Q2 2020 Aug 13, 2020	SELL	$3.32 - $5.34 $1.66 Million - $2.66 Million	-498,553 Reduced 37.89%	817,310 $3.76 Million
Q1 2020 May 14, 2020	BUY	$2.12 - $6.8 $2.53 Million - $8.1 Million	1,191,452 Added 957.67%	1,315,863 $4.49 Million
Q4 2019 Feb 14, 2020	SELL	$2.25 - $5.8 $219,480 - $565,772	-97,547 Reduced 43.95%	124,411 $634,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $1.58 Million - $2.41 Million	-710,283 Reduced 76.19%	221,958 $535,000
Q2 2019 Aug 14, 2019	SELL	$1.8 - $3.3 $2.58 Million - $4.74 Million	-1,435,774 Reduced 60.63%	932,241 $2.02 Million
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $2.71 Million - $6.65 Million	1,125,772 Added 90.62%	2,368,015 $6.42 Million
Q4 2018 Feb 14, 2019	BUY	$3.94 - $9.7 $1.27 Million - $3.12 Million	321,783 Added 34.96%	1,242,243 $5.96 Million
Q3 2018 Dec 21, 2021	BUY	$8.6 - $11.26 $3.72 Million - $4.87 Million	432,583 Added 88.67%	920,460 $8.72 Million
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $1.23 Million - $1.6 Million	142,518 Added 41.27%	487,877 $4.62 Million
Q2 2018 Apr 21, 2020	BUY	$9.52 - $12.15 $634,289 - $809,518	66,627 Added 23.9%	345,359 $3.36 Million
Q2 2018 Aug 14, 2018	SELL	$9.52 - $12.15 $6.52 Million - $8.32 Million	-684,915 Reduced 71.08%	278,732 $2.71 Million
Q1 2018 Oct 18, 2019	BUY	$6.7 - $12.95 $2.18 Million - $4.21 Million	324,971 Added 50.88%	963,647 $10.1 Million
Q1 2018 May 15, 2018	SELL	$6.7 - $12.95 $193,147 - $373,322	-28,828 Reduced 4.32%	638,676 $6.72 Million
Q4 2017 Feb 14, 2018	SELL	$5.07 - $7.92 $1.81 Million - $2.82 Million	-356,661 Reduced 34.82%	667,504 $4.28 Million
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $5.53 Million - $8.67 Million	1,024,165	1,024,165 $7.83 Million

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account